Taiwan's OBI Pharma Partners with Novartis to Develop Next-Generation Antibody-Drug Conjugates

industry_news

Taiwan's OBI Pharma Partners with Novartis to Develop Next-Generation Antibody-Drug Conjugates

Updated on Nov 14, 2026, 02:18 AM IST
Written & Edited by Harikesh VA

OBI Pharma, Inc. (4174.TWO) (“OBI”) has entered into a collaboration and licensing agreement with Novartis Pharma AG (“Novartis”) to advance the development of next-generation antibody-drug conjugates (ADCs) incorporating novel payloads through OBI’s proprietary technology platforms.

 

Collaboration Covers ADC Platform Technologies

Under the agreement, Novartis will obtain exclusive worldwide rights to OBI’s relevant patents and know-how associated with its ADC platform technologies for selected, undisclosed Novartis payload classes.

 

As part of the collaboration, OBI will also assess new linker approaches for use with Novartis’s payloads. The agreement provides Novartis with the option to extend the collaboration to cover additional novel payload classes.

 

The partnership represents a significant development for OBI, demonstrating the potential of its differentiated ADC technology platform. It also supports the company's efforts to broaden the international application of its proprietary technologies, including GlycOBI, EndoSymeOBI, HYPrOBI, and GlycOBI DUO, through strategic collaborations.

 

 

Companies Highlight ADC Development Potential

Ya-Chi Chen, Pharm.D., acting Chief Executive Officer of OBI Pharma, Inc., said, “We are delighted to enter into this agreement with Novartis, a leading pharmaceutical company in innovative oncology drug development with extensive commercialization capabilities. This agreement recognizes the scientific and commercial potential of OBI’s proprietary ADC technologies and reflects the value of our differentiated platform. By combining OBI’s ADC expertise with Novartis’s resources and capabilities, we aim to advance next-generation therapies that could deliver meaningful benefits to patients.”

 

Shiva Malek, Global Head of Oncology, Biomedical Research at Novartis, said, “Engaging with OBI’s expertise and technologies in antibody-drug conjugation to create potential ADCs with novel payloads is an important part of our oncology ADC strategy. This collaboration supports our ambition to innovate novel therapies and potentially expand treatment options for patients."

 

Trusted by Leading EPCs & Manufacturers

Find the Latest Pharmaceutical Plant Projects in the Asia-Pacific

Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information

Request Free Trial → Learn More →

No credit card Up-to-date coverage

 

Deal Includes USD 30 Million Upfront Payment

Under the financial terms, OBI will receive an upfront payment of USD 30 million. The company is also eligible for development, regulatory, and commercial milestone payments, taking the potential total value of the agreement to more than USD 2 billion.

 

In addition, OBI will be entitled to tiered royalties based on net sales of licensed products developed through the collaboration.

 

About Obrion ADC Technology

OBI's proprietary Obrion ADC Technology Platform combines multiple technologies designed to support the development of next-generation antibody-drug conjugates.

 

Its core technology, GlycOBI, uses glycan-based conjugation and features a flexible, plug-and-play design compatible with a broad range of antibodies, linkers, and payloads. The technology also supports different drug-to-antibody ratios (DARs).

 

GlycOBI works alongside OBI's proprietary dual-function enzymatic technology, EndoSymeOBI, and its highly hydrophilic and stable linker technology, HYPrOBI. Together, these technologies enable the efficient and scalable production of site-specific, homogeneous ADCs under good manufacturing practice (GMP) conditions.

 

The platform also includes GlycOBI DUO, which extends its capabilities to support advanced ADC formats, including dual-payload antibody-drug conjugates.

 

About OBI Pharma

Established in 2002 and headquartered in Taiwan, OBI Pharma is a clinical-stage oncology company with operations in the United States and Australia.

 

The company focuses on developing innovative cancer treatments and advancing proprietary antibody-drug conjugate technologies to address unmet medical needs and create additional treatment options for patients.

Stay Ahead of Every Chemical Sector Project Milestone Across the Asia-Pacific Region

What distinguishes the companies that secure contracts in the chemical sector from those that simply observe them being awarded? It’s all about timing and the insight to act on it first.

 

Across Asia-Pacific, billions of dollars in chemical sector projects transition from planning to execution every single quarter. The Global Project Tracking (GPT) platform by Blackridge Research consolidates this entire landscape into one dashboard, enabling your team to identify opportunities before competitors are even aware they exist.

 

Whether you are focusing on emerging markets or established centers in the chemical sector, gaining early insight into the project lifecycle transforms how you bid, forge partnerships, and allocate resources.

 

  • Upcoming Projects

  • Tender Notices

  • Contract Awards

  • Projects Under Construction

  • Completed Projects

 

Schedule a Free Demo today to discover how the Global Project Tracking (GPT) platform by Blackridge Research can enhance your insights into the chemical sector, giving you a competitive edge.

Tags

Leave a Comment

We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.

We read every comment and do our best to respond to them all.

Protected by Cloudflare Turnstile